Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.07
+0.58 (3.32%)
At close: Nov 5, 2025, 4:00 PM EST
18.10
+0.03 (0.17%)
After-hours: Nov 5, 2025, 7:11 PM EST
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Summit Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33.63, which forecasts a 86.11% increase in the stock price over the next year. The lowest target is $12 and the highest is $44.
Price Target: $33.63 (+86.11%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 9 | 10 | 9 | 9 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 16 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +121.36% | Oct 22, 2025 |
| Barclays | Barclays | Sell Maintains $13 → $16 | Sell | Maintains | $13 → $16 | -11.46% | Oct 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +121.36% | Oct 21, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $35 → $40 | Strong Buy | Maintains | $35 → $40 | +121.36% | Oct 20, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $40 | Buy | Reiterates | $40 | +121.36% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
18.90M
EPS This Year
-1.31
from -0.31
EPS Next Year
-1.02
from -1.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 86.1M | |||
| Avg | n/a | 18.9M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.14 | -0.59 | |||
| Avg | -1.31 | -1.02 | |||
| Low | -1.45 | -1.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.